AstraZeneca’s Other Products in 3Q17
The Other Products segment reported revenues of $991 million during 3Q17, a 17% fall in constant exchange rates compared to 3Q16.
AstraZeneca’s (AZN) Oncology segment reported revenues of ~$1 billion during 3Q17, a 19% growth at constant exchange rates.
AstraZeneca’s (AZN) Respiratory segment is one of its key growth platforms. For 3Q17, the segment’s revenues fell 2% at constant exchange rates to ~$1.1 billion.
Brilinta reported 36% growth in revenues at constant exchange rates to $284 million, while foreign exchange impacted its revenues positively by 1% during 3Q17.
The Respiratory segment reported a 2% fall in revenues at constant exchange rates to ~$1.1 billion during 3Q17.
The CVMD segment reported a 4% fall in revenues at constant exchange rates to ~$1.8 billion during 3Q17.
AstraZeneca’s (AZN) overall revenue growth was 9%, driven by a substantial growth in externalization revenues to $1.~4 billion, partially offset by a 2% fall in product sales.
In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.
Sanofi Pasteur reported revenues of 1.92 billion euros for 3Q17, which was 11% higher YoY (year-over-year) at constant exchange rates.
Sanofi’s generics business reported revenues of 433 million euros for 3Q17—a 0.9% YoY (year-over-year) fall.
For 3Q17, revenues from established prescription products fell 6.5% YoY (year-over-year) at constant exchange rates to 2.26 billion euros.
Sanofi’s diabetes and cardiovascular franchises include the blockbuster diabetes drug Lantus, which contributes ~70% of all revenues for diabetes products.
Sanofi’s Sanofi Genzyme franchise includes specialty care product revenues and reported revenue growth of 12.5% to 1.63 billion euros.
Sanofi reports its business in two segments: Human Pharmaceuticals and Sanofi Pasteur, or the Human Vaccines segment.
Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.
Sanofi’s 3Q17 earnings were released on November 2, 2017. It reported revenues of 9.05 billion euros for 3Q17, an operational growth of 4.7% YoY.
CVS Health’s (CVS) better-than-expected 3Q17 results failed to please investors. The company hit a three-and-a-half-year low as the stock price fell 3.5% to close at $66.80 on November 6.
As we discussed in the previous part of this series, CVS Health (CVS) reported a 135 basis point drop in its gross margin to 15.4% of sales.
As we’ve discussed, CVS Health (CVS) cruised ahead of Wall Street’s bottom-line expectations when it reported its third-quarter results on November 6.
As we’ve discussed, CVS Health (CVS) reported its 3Q17 results on November 6. The company’s top line improved 3.5% YoY (year-over-year) to $46.2 billion.